Aptiv Solutions

CROs juggle proprietary and commercial systems

Tuesday, March 15, 2016

Third-party vendors have come to dominate the clinical trial technology sector, which was led by CROs a decade ago. At the same time, many large CROs continue to invest in technology solutions to differentiate their services and offer greater efficiencies in clinical development processes.

[Read More]

Bracket names Matt Bond CFO

Monday, November 16, 2015

Bracket, a global clinical trial specialty services provider, has announced the addition of J. Matthew Bond as chief financial officer and as a member of the company’s leadership team.

[Read More]

ICON appoints two in Asia Pacific operations

Monday, October 26, 2015

ICON, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, has announced two new leadership appointments to its Asia Pacific operations. Mary Pan has been appointed vice president, Asia Pacific, where she will lead ICON’s continued growth and expansion in the region. Hiroshi Ichikawa has been appointed vice president and general manager of ICON’s operations in Japan.

[Read More]

inVentiv Health names Michael McKelvey EVP, Clinical division president

Friday, June 5, 2015

Global CRO inVentiv Health has appointed Michael McKelvey, Ph.D., president, inVentiv Health Clinical Division, and executive vice president, inVentiv Health. McKelvey is a seasoned veteran within the CRO industry and has a strong background in clinical development, technology and the development of innovative industry strategies. McKelvey has extensive experience in building and managing successful global organizations in the pharmaceutical services, healthcare, information technologies, life sciences, technology and global core laboratory industries.  

[Read More]

Pfizer, Roche join ADDPLAN DF Consortium

Monday, August 4, 2014

Pfizer and Roche have joined the ADDPLAN DF Consortium. The consortium was founded in 2013 by Novartis, Janssen PharmaceuticalsEli Lilly and Aptiv Solutions, an Icon company, to lead the design and implementation of adaptive trials. The goal of the ADDPLAN DF Consortium is to develop methodologies and execution technologies that improve dose-selection, which remains a major barrier to resolving high failure rates in phase III trials.

[Read More]

Aptiv Solutions launches ADDPLAN DF 3.0

Wednesday, May 14, 2014

Aptiv Solutions, an Icon company focused on the design and implementation of adaptive trials, has released ADDPLAN DF 3.0, which incorporates complex statistical methodologies to prevent under- and over-estimation of a therapeutic’s maximum target dose (MTD) during phase I dose escalation trials.

[Read More]